Provenance Record

Well-structured News piece following the Overview / What We Know / What We Don't Know / Analysis format. Appropriate technical depth for a Phase 3 oncology readout; clearly separates confirmed topline data from what remains outstanding (median PFS, response rates, mature OS).

All three snapshots read from disk and verified. source-0.html.gz (BioSpace, HTTP 200): confirms the 43% risk reduction, HR=0.57 (95% CI 0.43, 0.76; p<0.0001), 510 patients across 176 sites, MANGROVE/BGB-3111-306/NCT04002297 identifiers, the verbatim Amit Agarwal quote, the '290,000 patients / 80 markets' figures, the 'rare and typically aggressive (fast-growing) type of B-cell non-Hodgkin lymphoma' description, and 'global regulatory submissions are planned for 2H 2026' (article renders this as 'second half of 2026', which is faithful). source-1.html.gz (CancerNetwork, HTTP 200): confirms the population (patients 70 years and older, or 60-69 with comorbidities precluding autologous stem cell transplantation), dosing (zanubrutinib 160 mg BID, rituximab 375 mg/m2, bendamustine 90 mg/m2), and that full data will be presented at an upcoming medical meeting. source-2.html.gz (StockTitan, HTTP 200): confirms the six-cycle BR comparator, zanubrutinib monotherapy continuation, OS immature with a strong favorable trend, and the chemotherapy-free / rituximab-maintenance-free framing sparing ~two years of infusions.

Every specific (percentages, hazard ratio, confidence interval, p-value, patient counts, site count, doses, trial identifiers, market/patient figures) traces to the source it is attributed to. The single Rule 9 attribution worth flagging -- '2H 2026' rendered as 'second half of 2026' and attributed to BioSpace -- is accurate; BioSpace does contain that statement. Direct quote reproduced verbatim. No hallucinations detected.

High-quality, fully sourced News submission. All three sources verified from committed snapshots; every claim, quote, number, and name is supported. No bidirectional source gap (all three body URLs appear in article.sources). Approved for publication.